title: [Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
abstract: In a retrospective analysis, we compared the effectiveness and tolerability of gemcitabine (GEM) plus uracil/tegafur and cyclophosphamide with single-agent GEM as 1st-line chemotherapy for unresectable or recurrent pancreatic cancer. 33 patients received combination therapy and 25 patients were treated with GEM alone. Tumor response rate was 14.3% vs 8.7%, median progression-free survival was 3.2 vs 4 months, and median survival time was 6.5 vs 6.5 months in the combination and GEM groups, respectively. Complete response was observed just in 2 cases of the combination group, and 1 of them has been relapse-free for 3 years. In a subgroup of patients with good performance status, combination therapy prolonged median survival time significantly (9.4 vs 6.2 months). This combination therapy is well tolerated and may provide superior benefits to GEM monotherapy.
authors.affiliation: Dept. of Gastrointestinal and Hepatobiliary Oncology, Hyogo Cancer Center.
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Niki
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuda
authors.forename: Kazutsugu
authors.initials: K
authors.lastname: Horita
authors.forename: Shigeya
authors.initials: S
authors.lastname: Hirohata
authors.forename: Hogara
authors.initials: H
authors.lastname: Nishisaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014498:Uracil / Q000009:adverse effects / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D003520:Cyclophosphamide; D000093542:Gemcitabine